Improving the prognosis of patients after radical cystectomy. Part II: the role of perioperative chemotherapy.
In this review we analyse the current status of perioperative systemic chemotherapy in the treatment of transitional cell carcinoma (TCC) of the bladder; instead of summarizing each neoadjuvant or adjuvant clinical trial we focus on the advantages and disadvantages of both strategies on the basis of theoretical considerations, and outline a rationale for a better design of future studies to confirm the efficacy of perioperative chemotherapy in TCC.
Suttmann
Henrik
H
Department of Urology and Paediatric Urology, Saarland University Hospital, Homburg/Saar, Germany. henrik.suttmann@uniklinikum-saarland.de
Kamradt
Jörn
J
Lehmann
Jan
J
Stöckle
Michael
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D015653:Cystectomy; D006801:Humans; D019990:Perioperative Care / Q000379:methods; D011379:Prognosis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000628:therapy